宜宾埋线法双眼皮在线咨询宜宾激光祛斑亲身经历,宜宾做双眼皮哪家医院好,宜宾整形鼻子多少钱,宜宾脸部抽脂填充多少钱,宜宾假体隆鼻大约多少钱,宜宾哪家整形医院做脂肪填充面部好,宜宾玻尿酸打鼻子维持多久

The romance between "Sweetener" singer Ariana Grande and "SNL" performer Pete Davidson has turned sour.The couple, whose whirlwind romance-turned-engagement powered the celebrity gossip machine through the summer, has split, a source close to the singer tells CNN.Davidson confirmed their engagement in June. They had been dating a few weeks at the time. 362

The University of Florida issued a statement of apology on Sunday, one day after several black students were removed from the stage by a white faculty member during the university's commencement. Video of the incident showed the graduates celebrating their walk down the graduation aisle by dancing, when the usher grabbed the students. University of Florida President W. Kent Fuchs released a statement, saying the staffer was "inappropriately aggressive."  496

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The U.S. has now surpassed 17 million confirmed cases of COVID-19 and has yet again recorded more than 1 million cases of the virus in less than a week, according to a database kept by Johns Hopkins University.The U.S. reached the 16 million case threshold over the weekend. According to the COVID Tracking Project, the country is averaging more than 200,000 new cases of the virus every day, putting it on pace to record 1 million cases every five days.Since Oct. 30, the U.S. has recorded more than 8 million cases of COVID-19 — a number that represents 47% of all cases recorded since the virus reached the U.S. in January. The U.S. is currently in the midst of the most deadly stretch of the pandemic to date. The country surpassed 300,000 deaths linked to the virus on Monday. Since then, nearly 8,000 more people have died of the disease.The COVID Tracking Project reports that the U.S. has averaged more than 2,500 deaths every for the last week — and that number will likely increase in the weeks to come. The COVID Tracking Project also reports that record numbers of Americans are battling the virus in a hospital. The group says more than 113,000 people are currently hospitalized with the virus, leading many health care facilities — particularly those in rural areas — to reach maximum capacity levels.Spikes in COVID-19 typically trail behind spikes in cases and hospitalizations, meaning death totals will likely only increase in the weeks to come. 1481

The Wisconsin Department of Justice's special agent, Kozak, has been on the job for two and a half months.During that short time, he's accomplished a lot more than any human is capable of. Yes, that's right. Kozak is a four-legged special agent.He's a yellow Labrador that's received four months of training on how to sniff out electronic storage devices: cell phones, thumb drives, tiny memory cards and more.He is one of 30 dogs nationwide trained to smell a chemical compound found inside of these devices. To put it simply, he can smell a glue that humans can't."It's an adhesive that's used in the motherboards of electronic devices that contain storage," said Special Agent Joe Mech, who heads the DOJ's Internet Crimes Against Children division.Mech explained why this canine's job is so essential."Kozak helps us find storage devices that may contain child pornography or child exploitation material," he said.Mech said criminals try to hide the electronic evidence in their homes and sometimes human investigators will overlook them. Kozak sits and huffs when he locates any electronic storage device.But Kozak also works on homicide, drug and missing persons cases, too, anything where electronic storage units are involved.He is deployed all over the state of Wisconsin. Recently, Kozak helped search the home of missing teenager Jayme Closs. Mech said he believed he recovered a tablet in that search.Mech said he's been used eight times so far, recovering 14 devices.Mech said it's too early to tell if the evidence he recovered will help in the cases.So how did the DOJ end up having a dog like this? Kozak's handler, Special Agent Tami Pawlak, said the department has this canine all because of a woman from Pittsburgh, Alicia Kozakiewicz.When she was 13-years-old, a man kidnapped Kozakiewicz and held her hostage, posting videos of her abuse online. Now 30 years old, Kozakiewicz raises awareness about child sexual exploitation online.Alicia's Law passed in many states, including Wisconsin. Money from it provides funding for dogs like Kozak, which can be very expensive. The initial cost of Kozak and his training totals ,000.The DOJ said initial funding from Alicia's Law was million. An additional .5 million was granted for this current biennium."One thousand predators have been arrested in the last two years since Alicia's Law has passed," said Kozakiewicz.In case you are wondering, yes. Kozak is named after Kozakiewicz."Alicia is a warrior, so it was an honor to be able to name our dog after her," said Special Agent Pawlak.One day, Kozakiewicz and Kozak hope to meet."He's going to help so many lives and put so many bad people away," Kozakiewicz said.Kozak is the only dog in Wisconsin doing this type of work. As of right now, the DOJ doesn't have any plans to bring another on board.In the meantime, Kozak found his niche. Pawlak said he was initially trained as a citizen service dog, but because he was so hyper, he flunked out of his course.Another trainer got a hold of him and his high energy and motivation for food made him a perfect fit for his new role.  3168